Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Inactivation of the p53 pathway in retinoblastoma.

Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, Teunisse A, Lam S, Ramos Y, Mohan A, Johnson D, Wilson M, Rodriguez-Galindo C, Quarto M, Francoz S, Mendrysa SM, Guy RK, Marine JC, Jochemsen AG, Dyer MA.

Nature. 2006 Nov 2;444(7115):61-6.

PMID:
17080083
2.

Cancer biology: second step to retinal tumours.

Wallace VA.

Nature. 2006 Nov 2;444(7115):45-6. No abstract available.

PMID:
17080077
3.

Oncogenic functions of hMDMX in in vitro transformation of primary human fibroblasts and embryonic retinoblasts.

Lenos K, de Lange J, Teunisse AF, Lodder K, Verlaan-de Vries M, Wiercinska E, van der Burg MJ, Szuhai K, Jochemsen AG.

Mol Cancer. 2011 Sep 12;10:111. doi: 10.1186/1476-4598-10-111.

4.

Regulation of p14ARF expression by miR-24: a potential mechanism compromising the p53 response during retinoblastoma development.

To KH, Pajovic S, Gallie BL, Thériault BL.

BMC Cancer. 2012 Feb 15;12:69. doi: 10.1186/1471-2407-12-69.

5.

Co-deleting Pten with Rb in retinal progenitor cells in mice results in fully penetrant bilateral retinoblastomas.

Xie C, Lu H, Nomura A, Hanse EA, Forster CL, Parker JB, Linden MA, Karasch C, Hallstrom TC.

Mol Cancer. 2015 Apr 24;14:93. doi: 10.1186/s12943-015-0360-y.

6.

Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies.

Rushlow DE, Mol BM, Kennett JY, Yee S, Pajovic S, Thériault BL, Prigoda-Lee NL, Spencer C, Dimaras H, Corson TW, Pang R, Massey C, Godbout R, Jiang Z, Zacksenhaus E, Paton K, Moll AC, Houdayer C, Raizis A, Halliday W, Lam WL, Boutros PC, Lohmann D, Dorsman JC, Gallie BL.

Lancet Oncol. 2013 Apr;14(4):327-34. doi: 10.1016/S1470-2045(13)70045-7. Epub 2013 Mar 13.

7.

Rb suppresses human cone-precursor-derived retinoblastoma tumours.

Xu XL, Singh HP, Wang L, Qi DL, Poulos BK, Abramson DH, Jhanwar SC, Cobrinik D.

Nature. 2014 Oct 16;514(7522):385-8. doi: 10.1038/nature13813. Epub 2014 Sep 24.

8.

Growth suppression by a p14(ARF) exon 1beta adenovirus in human tumor cell lines of varying p53 and Rb status.

Saadatmandi N, Tyler T, Huang Y, Haghighi A, Frost G, Borgstrom P, Gjerset RA.

Cancer Gene Ther. 2002 Oct;9(10):830-9.

9.

Identification and characterization of the first small molecule inhibitor of MDMX.

Reed D, Shen Y, Shelat AA, Arnold LA, Ferreira AM, Zhu F, Mills N, Smithson DC, Regni CA, Bashford D, Cicero SA, Schulman BA, Jochemsen AG, Guy RK, Dyer MA.

J Biol Chem. 2010 Apr 2;285(14):10786-96. doi: 10.1074/jbc.M109.056747. Epub 2010 Jan 15.

10.

Cyclin G1 has growth inhibitory activity linked to the ARF-Mdm2-p53 and pRb tumor suppressor pathways.

Zhao L, Samuels T, Winckler S, Korgaonkar C, Tompkins V, Horne MC, Quelle DE.

Mol Cancer Res. 2003 Jan;1(3):195-206.

11.

Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis.

Edamoto Y, Hara A, Biernat W, Terracciano L, Cathomas G, Riehle HM, Matsuda M, Fujii H, Scoazec JY, Ohgaki H.

Int J Cancer. 2003 Sep 1;106(3):334-41.

12.

Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.

Watanabe T, Katayama Y, Yoshino A, Komine C, Yokoyama T.

Clin Cancer Res. 2003 Oct 15;9(13):4884-90.

13.

MDMX exerts its oncogenic activity via suppression of retinoblastoma protein.

Zhang H, Hu L, Qiu W, Deng T, Zhang Y, Bergholz J, Xiao ZX.

Oncogene. 2015 Oct 29;34(44):5560-9. doi: 10.1038/onc.2015.11. Epub 2015 Feb 23.

PMID:
25703327
14.

Compensation by tumor suppressor genes during retinal development in mice and humans.

Donovan SL, Schweers B, Martins R, Johnson D, Dyer MA.

BMC Biol. 2006 May 3;4:14.

15.

MdmX represses E2F1 transactivation.

Wunderlich M, Ghosh M, Weghorst K, Berberich SJ.

Cell Cycle. 2004 Apr;3(4):472-8. Epub 2004 Apr 1.

PMID:
14739777
16.

A small-molecule inhibitor of MDMX activates p53 and induces apoptosis.

Wang H, Ma X, Ren S, Buolamwini JK, Yan C.

Mol Cancer Ther. 2011 Jan;10(1):69-79. doi: 10.1158/1535-7163.MCT-10-0581. Epub 2010 Nov 12.

17.

Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation.

Nittner D, Lambertz I, Clermont F, Mestdagh P, Köhler C, Nielsen SJ, Jochemsen A, Speleman F, Vandesompele J, Dyer MA, Schramm A, Schulte JH, Marine JC.

Nat Cell Biol. 2012 Sep;14(9):958-65. doi: 10.1038/ncb2556. Epub 2012 Aug 5.

PMID:
22864477
18.

RB1 gene inactivation by chromothripsis in human retinoblastoma.

McEvoy J, Nagahawatte P, Finkelstein D, Richards-Yutz J, Valentine M, Ma J, Mullighan C, Song G, Chen X, Wilson M, Brennan R, Pounds S, Becksfort J, Huether R, Lu C, Fulton RS, Fulton LL, Hong X, Dooling DJ, Ochoa K, Mardis ER, Wilson RK, Easton J, Zhang J, Downing JR, Ganguly A, Dyer MA.

Oncotarget. 2014 Jan 30;5(2):438-50.

19.

Nucleolar p14(ARF) overexpression in Reed-Sternberg cells in Hodgkin's lymphoma: absence of p14(ARF)/Hdm2 complexes is associated with expression of alternatively spliced Hdm2 transcripts.

García JF, Villuendas R, Sánchez-Beato M, Sánchez-Aguilera A, Sánchez L, Prieto I, Piris MA.

Am J Pathol. 2002 Feb;160(2):569-78.

20.

Expression of p14ARF, MDM2, and MDM4 in human retinoblastoma.

Guo Y, Pajovic S, Gallie BL.

Biochem Biophys Res Commun. 2008 Oct 10;375(1):1-5. doi: 10.1016/j.bbrc.2008.07.055. Epub 2008 Jul 21.

Supplemental Content

Support Center